Venous thromboembolism following initiation of atypical antipsychotics in two geriatric patients.
Background
Although not formally highlighted as a risk factor in current practice guidelines, several observational studies have reported a possible association between antipsychotic use and development of venous thromboembolism (VTE). However, it is unclear to what extent the risk is elevated.


Case Report
Described are 2 cases of VTE following recent initiation of second-generation antipsychotics in elderly patients. Ms A was a 65-year-old woman with newly diagnosed bipolar I disorder who was hospitalized for acute mania and psychosis. She was treated with risperidone along with traditional mood stabilizers and developed a pulmonary embolism shortly after treatment initiation. Ms B was a 77-year-old woman with newly diagnosed bipolar I disorder who was hospitalized for depression and psychosis. She was treated with quetiapine and electroconvulsive therapy and developed a pulmonary embolism and deep vein thrombosis within 2 months of starting treatment. Risk assessment tools were not able to definitively predict the VTEs that developed in our patients.


Conclusion
The association between antipsychotic medication and VTE has shown the highest risk with atypical antipsychotics, high dosages, and initiation within the past 3 months. Risk assessment tools may assist in assessing the risk of VTE in patients on antipsychotic therapy, although patients who are deemed by these tools to have minimal risk can still develop a VTE. Discussing VTE risk with patients when considering antipsychotic usage may help clinicians and patients safely determine the most appropriate treatment for their psychiatric illnesses while mitigating potential adverse effects.
['Maestri|Thomas J|TJ|0000-0002-1332-3023', 'Koenig|Jessica|J|0000-0002-9562-0047', 'Masuda|Christine|C|0000-0002-4083-9623', 'Smith|Tawny L|TL|0000-0002-7512-4919', 'Garcia-Pittman|Erica C|EC|0000-0002-6835-1910']
venous thromboembolism antipsychotic antipsychotic geriatric risk VTE antipsychotics